Moderate to Severe Plaque-type Psoriasis
5 clinical trials · Condition
◉ Watch Moderate to Severe Plaque-type Psoriasis
| Record | Firm | Date |
|---|---|---|
| Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis (NCT02474069) | Novartis Pharmaceuticals | 2015-02-08 |
| Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab (NCT01544595) | Novartis Pharmaceuticals | 2012-06-19 |
| First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (NCT01555125) | Novartis Pharmaceuticals | 2012-05-08 |
| Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (NCT01406938) | Novartis Pharmaceuticals | 2011-08-01 |
| Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (NCT01365455) | Novartis Pharmaceuticals | 2011-06-01 |
Track Moderate to Severe Plaque-type Psoriasis automatically
Every clearance here is in the API, with alerts when new ones post.